Published online before print September 3, 2002, doi: 10.1161/01.CIR.0000034044.95911.DC
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:1943.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans
From the Department of Clinical Pharmacology (T.S., D.L., A.K., M.I., K.v.B.), University of Bonn, Germany; and Clinical Research (D.L.T., S.S., I.P.), Merck Research Laboratories, Rahway, NJ.
Correspondence to Prof Klaus von Bergmann, MD, Dept of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn/Germany. E-mail vonbergmann{at}uni-bonn.de
Background— Ezetimibe has been shown to inhibit cholesterol absorption in animal models, but studies on cholesterol absorption in humans have not been performed thus far.
Methods and Results— The effect of ezetimibe (10 mg/d) on cholesterol absorption and synthesis, sterol excretion, and plasma concentrations of cholesterol and noncholesterol sterols was investigated in a randomized, double-blind, placebo-controlled, crossover study in 18 patients with mild to moderate hypercholesterolemia. Treatment periods lasted 2 weeks with an intervening 2-week washout period. Fractional cholesterol absorption rates averaged 49.8±13.8% on placebo and 22.7±25.8% on ezetimibe, indicating a reduction of 54% (geometric mean ratio; P< 0.001). Cholesterol synthesis increased by 89% from 931±1027 mg/d on placebo to 1763±1098 mg/d on ezetimibe (P<0.001), while the ratio of lathosterol-to-cholesterol, an indirect marker of cholesterol synthesis, was increased by 72% (P<0.001). Bile acid synthesis was insignificantly increased (placebo: 264±209 mg/d, ezetimibe: 308±184 mg/d; P=0.068). Mean percent changes from baseline for LDL and total cholesterol after ezetimibe treatment were -20.4% and -15.1%, respectively (P<0.001 for both), whereas campesterol and sitosterol were decreased by -48% and - 41%, respectively.
Conclusion— In humans, ezetimibe inhibits cholesterol absorption and promotes a compensatory increase of cholesterol synthesis, followed by clinically relevant reductions in LDL and total cholesterol concentrations. Ezetimibe also reduces plasma concentrations of the noncholesterol sterols sitosterol and campesterol, suggesting an effect on the absorption of these compounds as well.
Key Words: ezetimibe • cholesterol absorption • cholesterol synthesis • lathosterol • plant sterols
This article has been cited by other articles:
 |
|
 |
|
  S. Helske, T. Miettinen, H. Gylling, M. Mayranpaa, J. Lommi, H. Turto, K. Werkkala, M. Kupari, and P. T. Kovanen Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves J. Lipid Res., July 1, 2008; 49(7): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Weingartner, D. Lutjohann, S. Ji, N. Weisshoff, F. List, T. Sudhop, K. von Bergmann, K. Gertz, J. Konig, H.-J. Schafers, et al. Vascular effects of diet supplementation with plant sterols. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1553 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tavridou, L. Kaklamanis, A. Papalois, A. P. Kourounakis, E. A. Rekka, P. N. Kourounakis, A. Charalambous, and V. G. Manolopoulos EP2306 [2-(4-Biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], A Novel Squalene Synthase Inhibitor, Reduces Atherosclerosis in the Cholesterol-Fed Rabbit J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 794 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S Sampalis, S. Bissonnette, R. Habib, S. Boukas, and for the Ezetrol Add-On Investigators Reduction in Estimated Risk for Coronary Artery Disease After Use of Ezetimibe with a Statin Ann. Pharmacother., September 1, 2007; 41(9): 1345 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Piorkowski, S. Fischer, C. Stellbaum, M. Jaster, P. Martus, A. J. Morguet, H.-P. Schultheiss, and U. Rauch Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone: Is Sufficient Cholesterol-Lowering Enough to Inhibit Platelets? J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1035 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Clarenbach, M. Reber, D. Lutjohann, K. von Bergmann, and T. Sudhop The lipid-lowering effect of ezetimibe in pure vegetarians J. Lipid Res., December 1, 2006; 47(12): 2820 - 2824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Westover, X. Lin, T. E. Riehl, L. Ma, W. F. Stenson, D. F. Covey, and R. E. Ostlund Jr. Rapid transient absorption and biliary secretion of enantiomeric cholesterol in hamsters J. Lipid Res., November 1, 2006; 47(11): 2374 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K Nies, A. A Cymbala, S. L Kasten, D. G Lamprecht, and K. L Olson Complementary and Alternative Therapies for the Management of Dyslipidemia Ann. Pharmacother., November 1, 2006; 40(11): 1984 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Tremblay, B. Lamarche, J. S. Cohn, J.-C. Hogue, and P. Couture Effect of Ezetimibe on the In Vivo Kinetics of ApoB-48 and ApoB-100 in Men With Primary Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1101 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Radermecker and A. J. Scheen Serum Plant Sterols and Atherosclerosis: Is There a Place for Statin-Ezetimibe Combination? J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1496 - 1497. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yu, S. Bharadwaj, J. M. Brown, Y. Ma, W. Du, M. A. Davis, P. Michaely, P. Liu, M. C. Willingham, and L. L. Rudel Cholesterol-regulated Translocation of NPC1L1 to the Cell Surface Facilitates Free Cholesterol Uptake J. Biol. Chem., March 10, 2006; 281(10): 6616 - 6624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jakulj, M. D. Trip, T. Sudhop, K. von Bergmann, J. J. P. Kastelein, and M. N. Vissers Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels J. Lipid Res., December 1, 2005; 46(12): 2692 - 2698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. During, H. D. Dawson, and E. H. Harrison Carotenoid Transport Is Decreased and Expression of the Lipid Transporters SR-BI, NPC1L1, and ABCA1 Is Downregulated in Caco-2 Cells Treated with Ezetimibe J. Nutr., October 1, 2005; 135(10): 2305 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G D Kolovou, K K Anagnostopoulou, and D V Cokkinos Pathophysiology of dyslipidaemia in the metabolic syndrome Postgrad. Med. J., June 1, 2005; 81(956): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F.H. Stalenhoef Management of mixed hyperlipidaemia Eur. Heart J., May 1, 2005; 26(9): 856 - 857. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Repa, S. D. Turley, G. Quan, and J. M. Dietschy Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption J. Lipid Res., April 1, 2005; 46(4): 779 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Spratt and M. A. Denke Utility of Currently Available Modes of Therapy in Reaching Lipid Goals J Am Osteopath Assoc, September 1, 2004; 104(9_suppl): 14S - 16S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Vaughan and A. M. Gotto Jr Update on Statins: 2003 Circulation, August 17, 2004; 110(7): 886 - 892. [Full Text] [PDF]
|
|
|
|
|
|
H. R. Davis Jr., L.-j. Zhu, L. M. Hoos, G. Tetzloff, M. Maguire, J. Liu, X. Yao, S. P. N. Iyer, M.-H. Lam, E. G. Lund, et al. Niemann-Pick C1 Like 1 (NPC1L1) Is the Intestinal Phytosterol and Cholesterol Transporter and a Key Modulator of Whole-body Cholesterol Homeostasis J. Biol. Chem., August 6, 2004; 279(32): 33586 - 33592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Salen, K. von Bergmann, D. Lutjohann, P. Kwiterovich, J. Kane, S.B. Patel, T. Musliner, P. Stein, B. Musser, and the Multicenter Sitosterolemia Study Group Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients With Sitosterolemia Circulation, March 2, 2004; 109(8): 966 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sehayek Genetic regulation of cholesterol absorption and plasma plant sterol levels: commonalities and differences J. Lipid Res., November 1, 2003; 44(11): 2030 - 2038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Berglund and D. Hyson Cholesterol Absorption and the Metabolic Syndrome: A New Look at an Old Area Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1314 - 1316. [Full Text] [PDF]
|
|
|
|
|
|
P. O. Kwiterovich Jr., S. C. Chen, D. G. Virgil, A. Schweitzer, D. R. Arnold, and L. E. Kratz Response of obligate heterozygotes for phytosterolemia to a low-fat diet and to a plant sterol ester dietary challenge J. Lipid Res., June 1, 2003; 44(6): 1143 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. F Mauro and C. E Tuckerman Ezetimibe for Management of Hypercholesterolemia Ann. Pharmacother., June 1, 2003; 37(6): 839 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Heek and H. Davis Pharmacology of ezetimibe Eur. Heart J. Suppl., December 1, 2002; 4(suppl_J): J5 - J8. [Abstract] [PDF]
|
|
|
|
|
|
C.M. Ballantyne Ezetimibe: efficacy and safety in clinical trials Eur. Heart J. Suppl., December 1, 2002; 4(suppl_J): J9 - J18. [Abstract] [PDF]
|
|